---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-093882"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:34:03.343802+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune granted Nasdaq extension to Dec 1, 2025 to regain $1 bid compliance

## Summary
- Nasdaq Hearings Panel granted exception until December 1, 2025 to meet minimum $1.00 bid price per share.
- Notice received on September 22, 2025; failure to comply by deadline will lead to delisting of ADSs.
- If non-compliant by December 1, 2025, trading will be suspended and delisting proceedings will commence.

## SEC filing metadata
- accession: 0001104659-25-093882
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/0001104659-25-093882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/adap-20250922x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-093882
- JSON: https://secwatch.observer/filing/0001104659-25-093882.json
- Plain text: https://secwatch.observer/filing/0001104659-25-093882.txt

## Key facts
- Listing & Compliance Notices
  Adaptimmune Therapeutics PLC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: September 22, 2025, Adaptimmune Therapeutics plc (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) confirming that the Company has been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). ​ The Company has until December 1, 2025 to regain compliance with the Bid Price Rule. Failure to regain compliance by December 1, 2025 will result in the delisting of the Company’s American Depositary Shares from The Nasdaq Capital Market. ​ Forward-Looking Stat
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/0001104659-25-093882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.